# DESCRIPTION

## BACKGROUND

- motivate pRNA 3WJ motifs

## DETAILED DESCRIPTION

- introduce RNA nanomotifs
- describe limitations of pRNA 3WJs
- disclose novel trifurcate pRNA 3WJ motifs
- describe self-assembly properties of pRNA
- measure thermodynamic parameters of pRNA 3WJs
- show greater stability of certain 3WJs
- describe effect of deletions on phi29 pRNA 3WJ stability
- describe effect of metal ions on pRNA 3WJ stability
- provide disclaimer on scope of disclosure
- define terms used in disclosure
- describe use of "a" and "an" in claims
- define "or combinations thereof"
- describe use of "about" and "approximately"
- define "substantially"
- describe use of "one embodiment"
- define "pharmaceutically acceptable"
- define "biologically active"
- define "pure" and "substantially pure"
- provide examples of animals
- define "treatment" and "prevention"
- define "therapeutic composition" and "pharmaceutical composition"
- define "effective amount"
- define "ameliorate"
- describe therapeutic benefit
- define "three-way junction" and "trifurcate" scaffold
- describe pRNA 3WJ construction
- describe branches of 3WJ domain
- describe non-Watson-Crick nucleotide pairs
- describe length of 3WJa, 3WJb, and 3WJc oligonucleotide sequences
- describe mutant constructs
- describe biophysical studies on deletion mutant constructs
- describe enhanced stability of deletion mutant constructs
- describe use of deletion mutant constructs as drug delivery scaffolds
- describe functional RNAs designed using deletion mutant constructs
- describe siRNA helix attached to 3WJ scaffold
- describe ribozyme function
- describe RNA aptamer function
- describe riboswitch function
- describe fusion of RNA moieties to 3WJ scaffolds
- describe advantages of RNA nanoparticles
- describe self-assembly of RNA nanoparticles
- describe multivalency of RNA nanoparticles
- describe targeted delivery of RNA nanoparticles
- describe nanoscale size of RNA nanoparticles
- describe controlled synthesis of RNA nanoparticles
- describe combination of therapy and detection in RNA nanoparticles
- describe protein-free nature of RNA nanoparticles
- describe safety of RNA nanoparticles

### Experimental

- introduce pRNA 3WJ construct design
- describe RNA oligomer assembly
- specify RNA strand sequences
- detail UV optical melting procedure
- explain thermodynamic parameter determination
- describe pRNA 3WJ secondary structure and free energy predictions
- introduce RNA secondary structure prediction programs
- detail free energy prediction methods
- correct for hairpin penalties
- discuss entropic penalties
- introduce electrophoretic gel mobility shift assays
- describe EMSA procedure
- report pRNA 3WJ nanomotif stabilities
- analyze melt curves
- discuss thermodynamic stabilities
- calculate free energies
- compare free energies to binding constants
- investigate uridine residue deletions
- evaluate RNA secondary structure prediction programs
- discuss metal ion binding effects
- depict metal ion binding effects
- analyze electrophoretic gel mobility shift assays
- confirm pRNA 3WJ formation
- introduce pRNA 3WJ constructs
- describe thermodynamic stability
- analyze loop-loop interaction stabilities
- discuss 3WJ stabilities
- explain structure-energetics relationships
- describe phi29 pRNA 3WJ crystal structure
- discuss base pairing and stacking
- evaluate free energy outputs
- compare predicted and measured stabilities
- introduce serum stability
- describe UV optical melting studies
- analyze degradation in human blood serum
- compare serum stability of 3WJ constructs
- discuss time course analysis
- determine melting temperatures
- introduce examples
- describe RNA junction scaffold
- define 3WJ construct
- describe branches of 3WJ construct
- discuss helical regions
- introduce embodiment with single unpaired nucleotide
- introduce embodiment with two adjacent unpaired nucleotides
- introduce embodiment with single unpaired nucleotide in second branch
- introduce embodiment with absent unpaired nucleotide
- describe 3WJa sequence
- describe 3WJb sequence
- describe 3WJc sequence
- describe RNA junction scaffold
- introduce phi29 pRNA 3WJ construct
- describe 3WJa sequence
- describe 3WJb sequence
- describe 3WJc sequence
- introduce M2 3WJ construct
- describe 3WJa sequence
- describe 3WJb sequence
- describe 3WJc sequence
- introduce SF5 3WJ construct
- describe 3WJa sequence
- describe 3WJb sequence
- describe 3WJc sequence
- introduce GA1 3WJ construct
- describe 3WJa sequence
- describe 3WJb sequence
- describe 3WJc sequence
- provide non-limiting examples of phi29 pRNA three-sequence sets
- provide non-limiting examples of M2 pRNA three-sequence sets
- provide non-limiting examples of SF5 pRNA three-sequence sets
- provide non-limiting examples of GA1 pRNA three-sequence sets
- describe generic phi29 pRNA 3WJ mutant constructs
- describe generic M2 pRNA 3WJ mutant constructs
- describe generic SF5 pRNA 3WJ mutant constructs
- describe generic GA1 pRNA 3WJ mutant constructs
- describe use of pRNA 3WJ constructs as scaffolds
- describe linking biologically active moieties to pRNA 3WJ domains
- describe conjugation of chemicals to RNA
- describe linking methods and biologically-active moieties
- claim RNA junction scaffold
- define RNA junction scaffold
- specify second branch absence
- specify third branch absence
- specify 3WJa sequence absence
- specify 3WJb sequence absence
- specify combined 3WJa and 3WJb sequence absence
- describe three-way junction domain
- describe modified three-way junction domain
- specify absence of unpaired nucleotide
- specify sequence IDs
- specify additional absence of unpaired nucleotide
- specify alternative sequence IDs
- specify combined absence of unpaired nucleotides
- specify alternative sequence IDs
- describe modified three-way junction domain
- specify sequence IDs
- describe modified three-way junction domain
- specify sequence IDs
- describe modified three-way junction domain
- describe conjugate composition
- describe pharmaceutical composition
- specify sequence length
- provide general disclosure statement

